BPM
VNDA icon

Bowling Portfolio Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Bowling Portfolio Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-22,419
Closed -$316K – 382
2019
Q2 		$316K Buy
+22,419
New +$357K 0.05% 295

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bowling Portfolio Management's VNDA Position: Q3 2019 in Review

Bowling Portfolio Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2019, closing a stake of 22,419 shares — an estimated $316K sold.

Bowling Portfolio Management first reported a position in VNDA in Q2 2019 and held it in 1 quarter. The position peaked at $316K in Q2 2019. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Bowling Portfolio Management reported no remaining Vanda Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Bowling Portfolio Management sold 22,419 Vanda Pharmaceuticals shares in Q3 2019, an estimated $316K.
  • Bowling Portfolio Management first reported a position in Vanda Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Bowling Portfolio Management's Vanda Pharmaceuticals position peaked at $316K in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Bowling Portfolio Management's 13F filing for Q3 2019, filed 15 Oct 2019.